Literature DB >> 2615291

[Mexiletine in terminal renal failure and various dialysis procedures].

J Evers1, W Messer, F Aboudan, K Finke.   

Abstract

We monitored the plasma levels of mexiletine in 20 dialysis patients with severe cardiac arrhythmias after repeated oral administration and the elimination by various dialysis procedures. The levels of mexiletine in plasma and dialysate were assayed by high-pressure liquid chromatography. After repeated administration of mexiletine 400-600 mg/day trough levels were in the range from 500-2,000 ng/ml. Treatment controlled by Holter monitoring was effective in 13/20 patients. Doses of 600 mg/day and more often were not tolerated by patients with dialysis after some weeks. There was no important removal of mexiletine from plasma during hemodialysis, hemofiltration, peritoneal dialysis, or plasmapheresis. In conclusion, we recommend a slightly reduced dosage of 400-600 mg mexiletine/day (usually 600-800 mg) for patients with end-stage renal insufficiency, irrespective of dialysis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2615291     DOI: 10.1007/bf01716063

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  9 in total

1.  [Treatment with mexiletine. Clinical and pharmacokinetic studies].

Authors:  H Breithaupt; A Schmidt
Journal:  Klin Wochenschr       Date:  1988-06-01

Review 2.  Mexiletine.

Authors:  R W Campbell
Journal:  N Engl J Med       Date:  1987-01-01       Impact factor: 91.245

3.  Liquid chromatographic determination of mexiletine and tocainide in human plasma with fluorescence detection after reaction with a modified o-phthalaldehyde reagent.

Authors:  R N Gupta; M Lew
Journal:  J Chromatogr       Date:  1985-11-08

4.  Mexiletine removal by peritoneal dialysis.

Authors:  T E Jones; P A Reece; G C Fisher
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  [Pharmacokinetic studies with mexiletine in patients with renal insufficiency].

Authors:  W Herbinger; R Kramar; M Fridrik; V Häselbarth; W P Pollmann
Journal:  Adv Clin Pharmacol       Date:  1978

6.  [Effect of kidney, liver or heart insufficiency on blood mexiletine levels].

Authors:  J Nitsch; G Steinbeck; B Lüderitz
Journal:  Internist (Berl)       Date:  1982-05       Impact factor: 0.743

Review 7.  Pharmacology and clinical use of mexiletine.

Authors:  P E Fenster; K A Comess
Journal:  Pharmacotherapy       Date:  1986 Jan-Feb       Impact factor: 4.705

8.  Pharmacokinetics and nondialyzability of mexiletine in renal failure.

Authors:  T Wang; D Wuellner; R L Woosley; W J Stone
Journal:  Clin Pharmacol Ther       Date:  1985-06       Impact factor: 6.875

9.  Pharmacokinetics of mexiletine in renal insufficiency.

Authors:  D El Allaf; L Henrard; L Crochelet; D Delapierre; J Carlier; A Dresse
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

  9 in total
  4 in total

1.  Influence of NaCl 0.9% Infusion during Plasmapheresis on IgG Content in Plasma.

Authors:  Josef Evers; Jochen Betz; Thomas Blankenburg; Tanja Engelen; Gabriele Galle; Michael Hansen; Teija Laitinen; Uwe Taborski
Journal:  Transfus Med Hemother       Date:  2010-07-14       Impact factor: 3.747

Review 2.  Drug Dosing in Patients Undergoing Therapeutic Plasma Exchange.

Authors:  Sherif Hanafy Mahmoud; Jessica Buhler; Eric Chu; Suzie A Chen; Theresa Human
Journal:  Neurocrit Care       Date:  2021-02       Impact factor: 3.210

Review 3.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 4.  Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.

Authors:  B Jarvis; A J Coukell
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.